DRG Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of colorectal cancer for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
DRG Epidemiology’s colorectal cancer forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with colorectal cancer per year?
How will improvements in survival change the number of people diagnosed with colorectal cancer per year?
How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for colorectal cancer?
How will the epidemiology of colorectal cancer be impacted in the countries with colorectal cancer screening programs?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of colorectal cancer over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following colorectal cancer subpopulations:
Diagnosed incident cases of colon cancer by stage at diagnosis.
Diagnosed incident cases of rectal cancer by stage at diagnosis.
Diagnosed prevalent cases of colon cancer by drug-treatment status.
Diagnosed prevalent cases of rectal cancer by drug-treatment status.
First-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
First-line drug-treatable colorectal cancer population (wild-type RAS) by treatment status.
Second-line drug-treatable colorectal cancer population (mutated RAS) by treatment status.
Second-line drug-treatable colorectal cancer population (wild-type RAS) by treatment status.
Diagnosed Incidence of Colorectal Cancer per 100,000 per Year Among People of All Ages in 2021 and 2031ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Incident Cases of Colorectal Cancer Over the Next 10 Yearsttttttttt
Analysis of the Diagnosed Incident Cases of Colorectal Cancer in 2021 by Stage Distribution
Number of Additional Diagnosed Incident Cases of Colorectal Cancer Incurred Over 2021-2031 in the Countries Under Study Due to Trends in Risk
Diagnosed Incident Cases
Stage Distribution of Colorectal Cancer
Recurrent Incident Cases of Colorectal Cancer
Diagnosed Prevalent Cases
Studies Included in the Analysis of Colorectal Cancer
Studies Excluded from the Analysis of Colorectal Cancer
Risk/Protective Factors for Colorectal Cancer
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.
Alexandre Vo Dupuy, Pharm.D., M.Sc.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.